AI-driven drug discovery, transforming medicine.

Isomorphic Labs is a London-based company founded in February 2021 by Demis Hassabis, operating as a subsidiary of Alphabet Inc. The company specializes in using artificial intelligence to revolutionize drug discovery, building on the groundbreaking AlphaFold system. With headquarters in London and an additional office in Lausanne, Switzerland, Isomorphic Labs employs a multidisciplinary team of drug discovery experts and AI specialists.

In April 2025, Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital, underscoring its rapid growth and potential. The company collaborates with major pharmaceutical firms such as Novartis and Eli Lilly to accelerate the development of life-changing medicines. While the exact number of employees is not publicly disclosed, the team is known to be expanding globally.